COMMUNIQUÉS West-GlobeNewswire

Healthcare Minus the Headache: RokketMed, A Solution to Finding the Care That Counts
06/11/2025
Turnkey San Francisco Platform Aims to Help All Employers and Workers SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- In the face of mounting healthcare compliance complexity and an urgent need for accessible [...]
Raise Craze, a partnership between the MUHC Foundation, The Beat 92.5, and Pink in the City, raised $162,160 for breast cancer care at the MUHC
06/11/2025
MONTREAL, Nov. 06, 2025 (GLOBE NEWSWIRE) -- During October’s Breast Cancer Awareness Month, the MUHC Foundation once again partnered with The Beat 92.5 and Pink in the City, raising an extraordinary $162,160 for breast [...]
La campagne Raise Craze, un partenariat entre la Fondation du CUSM, The Beat 92.5 et Pink in the City, recueille 162,160 $ pour les soins contre le cancer du sein au CUSM
06/11/2025
MONTRÉAL, 06 nov. 2025 (GLOBE NEWSWIRE) -- Dans le cadre du Mois de la sensibilisation au cancer du sein en octobre, la Fondation du CUSM s’est de nouveau associée à The Beat 92.5 et Pink in the City. La campagne a [...]
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
06/11/2025
EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Enovis Announces Third Quarter 2025 Results
06/11/2025
Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October [...]
Reviv Celebrates Over 20,000 Customers Worldwide
06/11/2025
A Global Phenomenon in Addressing TMJ Disorder and Related Health Issues Wilmington, DE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Reviv , a pioneering direct-to-consumer wellness brand, proudly announces a significant [...]
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
06/11/2025
4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all time points with up [...]
LifeStance Reports Third Quarter 2025 Results
06/11/2025
SCOTTSDALE, Ariz., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the third [...]
Privia Health Reports Third Quarter 2025 Financial Results
06/11/2025
Very Strong Third Quarter and Year-to-Date Performance Across the Business Net Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q’24 Implemented Providers +13.1% and Practice Collections +27.1% compared to 3Q’24 FY [...]
Novonesis delivered 8% organic sales growth in the first nine months of 2025
06/11/2025
Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark – November 6, 2025. Novonesis delivered 8% organic sales growth in the first nine [...]
BlueWillow Biologics’ Intranasal Bird Flu Vaccine Shows Signs of Broad Immune Response in Phase I Clinical Trial Published in Nature Communications
06/11/2025
New study published in Nature Communications paves the way for next-generation pandemic preparedness, demonstrating safety and immunogenicity of adjuvanted intranasal bird flu vaccine ANN ARBOR, Mich., Nov. 06, 2025 ( [...]
arcoris bio raises CHF 6.3 million seed round to advance next-generation biomarker technology for digital pathology
06/11/2025
Schlieren, Switzerland, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Round co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and new as well as existing private investors. MUSE ® , [...]
Immunocore reports third quarter financial results and provides a business update
06/11/2025
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM trial on track to [...]
ProQR Announces Third Quarter 2025 Operating and Financial Results
06/11/2025
Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseases Initiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data [...]
TREOS Bio Announces Publication of Phase 1b Clinical Trial Results of PolyPEPI1018 Plus TAS-102 in Refractory MSS mCRC in JCO Oncology Advances
06/11/2025
First study to report promising activity for an active immunotherapy combined with TAS-102 (LONSURF®) in late-stage MSS mCRC; TREOS advances Phase II programme with Charité – Universitätsmedizin Berlin and Junshi [...]
American Shared Hospital Services Announces Third Quarter Financial Results Conference Call
06/11/2025
Call Scheduled for November 13 th at 1:00 PM ET SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery [...]
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
06/11/2025
One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and [...]
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
06/11/2025
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a synergistic early-stage [...]
Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases
06/11/2025
Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead [...]

Pages